Key Highlights
- Shares of IBM have declined 19% from their mid-July highs following a disappointing second-quarter earnings report that missed revenue projections.
- Susquehanna’s James Friedman increased his price objective to $235 from $225 while maintaining a Neutral stance on the stock.
- The company’s quantum computing initiatives are attracting increased analyst focus despite contributing minimal revenues at present.
- An IBM senior vice president offloaded $5.75 million in company shares late in August.
- Industry observers are pointing to September’s Quantum World Congress as a potential near-term catalyst for investor sentiment.
Shares of International Business Machines opened Monday’s trading session at $235.78, positioned closer to its 52-week floor of $199.19 than its annual peak of $332.46. The stock has surrendered 19% of its value since mid-July, during which time the broader S&P 500 index advanced 2.1%.
International Business Machines Corporation, IBM
The downturn accelerated following a historic single-session decline triggered by IBM’s second-quarter earnings pre-announcement. While the technology giant delivered earnings per share of $2.93 that aligned with Wall Street expectations, quarterly revenue of $17.16 billion came in below the anticipated $17.46 billion. Top-line growth registered at a modest 1.1% compared to the prior year.
A significant headwind impacting performance is the reallocation of client spending toward artificial intelligence infrastructure, diverting capital away from IBM’s legacy product portfolio.
Quantum Computing Takes Center Stage
As traditional revenue streams face challenges, IBM’s quantum computing operations have emerged as a focal point for market watchers. Susquehanna’s Friedman drew attention to the company’s acquisition of HRL Laboratories and its collaboration with the Department of Commerce to establish Anderon, a dedicated quantum chip manufacturing facility.
The company has pursued quantum computing research for over two decades and has been instrumental in significant scientific achievements within the field. However, this division continues to produce negligible revenue, with widespread commercial adoption contingent upon substantial technological progress anticipated to materialize before decade’s end.
While elevating his price target to $235 from $225, Friedman retained his Neutral rating on the shares. He identified the upcoming Quantum World Congress scheduled for late September as a potential short-term driver for renewed investor attention toward the technology.
The analyst also noted additional developments: a strategic pivot toward software within IBM’s consulting operations under new leadership, constrained Red Hat expansion as server supply bottlenecks ease, and a mainframe revenue timing issue where 40% of transactions delayed in the second quarter successfully closed early in the third.
Executive Divestiture and Institutional Activity
Senior Vice President Robert David Thomas executed a sale of 25,000 IBM shares on August 26 at an average transaction price of $230.32, generating proceeds of $5.76 million. This divestiture reduced his direct ownership position by 34.34%, leaving a remaining stake of 47,800 shares.
Meanwhile, institutional activity showed several firms expanding their positions during the second quarter. New Republic Capital grew its allocation by 144%, while Daiwa Securities Group increased its holdings to 251,572 shares valued at approximately $70.7 million.
Institutional investors and hedge funds collectively control 58.96% of outstanding IBM equity.
Wall Street’s consensus rating on IBM stands at “Moderate Buy” with an average price objective of $265.40. The stock garners sixteen Buy recommendations, eleven Hold ratings, and a single Sell call. Barclays maintains an Overweight rating with a $262 price target, while JPMorgan carries an Overweight designation with a $250 objective.
The company’s upcoming quarterly dividend payment of $1.69 per share is set for distribution on September 10.


